Life course exposures continually shape antibody profiles and risk of seroconversion to influenza.
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
11
03
2020
accepted:
14
05
2020
entrez:
24
7
2020
pubmed:
24
7
2020
medline:
25
8
2020
Statut:
epublish
Résumé
Complex exposure histories and immune mediated interactions between influenza strains contribute to the life course of human immunity to influenza. Antibody profiles can be generated by characterizing immune responses to multiple antigenically variant strains, but how these profiles vary across individuals and determine future responses is unclear. We used hemagglutination inhibition titers from 21 H3N2 strains to construct 777 paired antibody profiles from people aged 2 to 86, and developed novel metrics to capture features of these profiles. Total antibody titer per potential influenza exposure increases in early life, then decreases in middle age. Increased titers to one or more strains were seen in 97.8% of participants during a roughly four-year interval, suggesting widespread influenza exposure. While titer changes were seen to all strains, recently circulating strains exhibited the greatest titer rise. Higher pre-existing, homologous titers at baseline reduced the risk of seroconversion to recent strains. After adjusting for homologous titer, we also found an increased frequency of seroconversion against recent strains among those with higher immunity to older previously exposed strains. Including immunity to previously exposures also improved the deviance explained by the models. Our results suggest that a comprehensive quantitative description of immunity encompassing past exposures could lead to improved correlates of risk of influenza infection.
Identifiants
pubmed: 32702069
doi: 10.1371/journal.ppat.1008635
pii: PPATHOGENS-D-20-00493
pmc: PMC7377380
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1008635Subventions
Organisme : Medical Research Council
ID : MR/S004793/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_19012
Pays : United Kingdom
Organisme : NIA NIH HHS
ID : R56 AG048075
Pays : United States
Organisme : Department of Health
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 200187/Z/15/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/J008761/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R015600/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 200861/Z/16/Z
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : R01 AI114703
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
JAMA. 1989 Aug 11;262(6):779-83
pubmed: 2787416
PLoS One. 2018 May 24;13(5):e0197504
pubmed: 29795587
Nat Med. 2019 Jun;25(6):962-967
pubmed: 31160818
Sci Rep. 2017 Aug 16;7(1):8488
pubmed: 28814737
PLoS Pathog. 2012;8(12):e1003061
pubmed: 23271967
PLoS Biol. 2015 Mar 03;13(3):e1002082
pubmed: 25734701
J Infect Dis. 2014 Sep 1;210(5):684-92
pubmed: 24676208
Science. 2016 Nov 11;354(6313):722-726
pubmed: 27846599
Sci Rep. 2015 Jun 05;5:11013
pubmed: 26046930
Nat Commun. 2019 Apr 10;10(1):1660
pubmed: 30971703
Am J Epidemiol. 1982 May;115(5):736-51
pubmed: 7081204
Science. 2019 Oct 25;366(6464):499-504
pubmed: 31649200
PLoS Pathog. 2012;8(7):e1002802
pubmed: 22829765
Clin Infect Dis. 2020 Mar 3;70(6):1029-1037
pubmed: 31056675
Lancet. 2010 Mar 27;375(9720):1100-8
pubmed: 20096450
PLoS Biol. 2018 Aug 20;16(8):e2004974
pubmed: 30125272
J Exp Med. 1941 Oct 31;74(5):433-9
pubmed: 19871146
Science. 2004 Jul 16;305(5682):371-6
pubmed: 15218094
Lancet. 2018 Mar 31;391(10127):1285-1300
pubmed: 29248255
Nat Commun. 2011 Aug 09;2:423
pubmed: 21829185
Emerg Microbes Infect. 2019;8(1):1157-1167
pubmed: 31373538
PLoS Comput Biol. 2020 Jun 15;16(6):e1007989
pubmed: 32542015
Science. 2014 Nov 21;346(6212):996-1000
pubmed: 25414313
Nat Immunol. 2017 Apr;18(4):464-473
pubmed: 28192418
Vaccine. 1994 Oct;12(13):1185-9
pubmed: 7839722
Nat Immunol. 2019 May;20(5):613-625
pubmed: 30778243
Int J Epidemiol. 2017 Apr 1;46(2):e16
pubmed: 26875566
Pediatrics. 1991 Jun;87(6):823-8
pubmed: 2034485
Nat Rev Immunol. 2019 Jun;19(6):383-397
pubmed: 30837674
Clin Infect Dis. 2014 Aug 15;59(4):517-24
pubmed: 24825868
Euro Surveill. 2010 Nov 25;15(47):
pubmed: 21144441